CONTROL OF JUSTIFICATION FOR PHARMACOTHERAPY IN PSYCHIATRIC HOSPITAL PATIENTS WITH FRAILTY SYNDROME

The aim of the study was to assess the possibilities of controlling justification for pharmacotherapy in psychiatric hospital patients with frailty syndrome. To achieve this goal, the following tools were used: the GerontoNet ADR Risk Score and ADRROP scales for assessing the risk of adverse drug reactions in elderly patients, a list of potentially not recommended drugs for patients > 65 «STOPP/START criteria», as well as the Anticholinergic Cognitive Burden Scale and Section «Anticholinergic drugs with strong anticholinergic properties» of Beers criteria. The risk of complications of pharmacotherapy was higher in patients with frailty syndrome and was identified using the ADRROP scale with the predominance of such found factors as «Age > 70 years» and «Need for assistance with ≥ 1 activity of daily living». The study of the identified STOPP/START criteria did not demonstrate a statistically significant difference in the frequency of their occurrence, however, the prescription of some potentially not recommended drugs prevailed in patients without frailty syndrome. There was also a higher frequency of prescribing anticholinergic drugs with strong anticholinergic properties and a higher median of the total score in this group of patients. The study found a greater risk of adverse reactions in patients with the studied syndrome, which was associated rather with age-related changes in the body than with drug therapy provided in a psychiatric hospital. Nevertheless, the methods used to assess the prescribed treatment can increase safety of pharmacotherapy in patients with mental illness and frailty syndrome.